IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · IT
Area of research
Cancer Research · Molecular Biology
Research interest
Research interests include MicroRNA in disease regulation, Cancer-related molecular mechanisms research, Circular RNAs in diseases, and RNA modifications and cancer.
Circulating miR-22 Predicts TACE Response and Targets WEE1 in Hepatocellular Carcinoma
Circulating miR-22 Early Predicts TACE Non-Response and Targets WEE1 in Hepatocellular Carcinoma.
Extracellular vesicles deliver functional extrachromosomal DNA in FGFR2-amplified cancer of unknown primary
Circulating miR-22 Early Predicts TACE Non-Response and Targets WEE1 in Hepatocellular Carcinoma
Exploring the Common Mutational Landscape in Cutaneous Melanoma and Pancreatic Cancer.
Merkel Cell Carcinoma: An Updated Review Focused on Bone and Bone Marrow Metastases.
Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferation
Surfaces environmental monitoring of SARS-CoV-2: Loop mediated isothermal amplification (LAMP) and droplet digital PCR (ddPCR) in comparison with standard Reverse-Transcription quantitative polymerase chain reaction (RT-qPCR) techniques.
Predictive Factors for Sentinel Lymph Node Positivity in Melanoma Patients-The Role of Liquid Biopsy, MicroRNA and Gene Expression Profile Panels.
Vaccine-Based Immunotherapy for Oropharyngeal and Nasopharyngeal Cancers.
Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferation
Merkel Cell Carcinoma: An Updated Review Focused on Bone and Bone Marrow Metastases
Profibrotic Molecules Are Reduced in CRISPR-Edited Emery-Dreifuss Muscular Dystrophy Fibroblasts.
1461eP Exploring miRNA signatures as diagnostic biomarker in HNCUP
Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives.
Association of miR-146a-5p and miR-21-5p with Prognostic Features in Melanomas.
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
Circulating <scp>microRNAs</scp> and <scp>isomiRs</scp> as biomarkers for the initial insult and epileptogenesis in four experimental epilepsy models: The <scp>EPITARGET</scp> study
The 2024 Nobel Prize in Physiology or Medicine: microRNA Takes Center Stage.
Circulating microRNAs and isomiRs as biomarkers for the initial insult and epileptogenesis in four experimental epilepsy models: The EPITARGET study.
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma
Anti–miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response
Disclosing quantitative <scp>RT‐PCR</scp> raw data during manuscript submission: a call for action
Settling the uncertainty about unconventional circulating tumor cells: Epithelial-to-mesenchymal transition, cell fusion and trogocytosis.
Diagnostic and Prognostic Value of microRNAs in Patients with Laryngeal Cancer: A Systematic Review.
A Systematic Review of Diagnostic and Prognostic Biomarkers for Head and Neck Cancer of Unknown Primary: An Unmet Clinical Need.
Disclosing quantitative RT-PCR raw data during manuscript submission: a call for action.
MiR-4646-5p Acts as a Tumor-Suppressive Factor in Triple Negative Breast Cancer and Targets the Cholesterol Transport Protein GRAMD1B.
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
Data from Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma